Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity
Authors
Keywords
Glucagon-like peptide-1, Type 2 diabetes, Obesity, Cardiovascular disease, Weight loss, Incretin
Journal
Current Obesity Reports
Volume 8, Issue 3, Pages 284-291
Publisher
Springer Science and Business Media LLC
Online
2019-05-23
DOI
10.1007/s13679-019-00350-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- The Origin and Understanding of the Incretin Concept
- (2018) Jens F. Rehfeld Frontiers in Endocrinology
- Recent updates on GLP-1 agonists: Current advancements & challenges
- (2018) Dilip Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
- (2018) Andrei C. Sposito et al. Cardiovascular Diabetology
- Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999–2010
- (2017) Nana Zhang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
- (2017) Matthew H. Secrest et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Obesity
- (2017) Sharon M. Fruh Journal of the American Association of Nurse Practitioners
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study
- (2016) DIABETES CARE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical Analysis
- (2016) David D. Kim et al. VALUE IN HEALTH
- Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
- (2015) Rhonda Bentley-Lewis et al. AMERICAN HEART JOURNAL
- The Global Burden of Obesity and the Challenges of Prevention
- (2015) Jacob C. Seidell et al. ANNALS OF NUTRITION AND METABOLISM
- Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
- (2015) Cristina Hernández et al. DIABETES
- Type-2 diabetes: Current understanding and future perspectives
- (2015) Ankita Pandey et al. IUBMB LIFE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity
- (2015) Benedikt A. Aulinger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management
- (2014) William T. Cefalu et al. DIABETES CARE
- Exendin-4 alleviates retinal vascular leakage by protecting the blood–retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats
- (2014) Yichao Fan et al. EXPERIMENTAL EYE RESEARCH
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013
- (2014) Marie Ng et al. LANCET
- Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells
- (2014) Mariola Dorecka et al. Pharmacological Reports
- Gastric and intestinal satiation in obese and normal weight healthy people
- (2014) Anne C. Meyer-Gerspach et al. PHYSIOLOGY & BEHAVIOR
- Euglycemic progression: Worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities
- (2013) A. Shurter et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
- (2013) S. Calanna et al. DIABETOLOGIA
- Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
- (2013) Young-Sun Lee et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
- (2013) Andrea Mari et al. PLoS One
- Gastric emptying, mouth-to-cecum transit, and glycemic, insulin, incretin, and energy intake responses to a mixed-nutrient liquid in lean, overweight, and obese males
- (2012) Radhika V. Seimon et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
- (2012) Dhanwantee Mundil et al. Diabetes & Vascular Disease Research
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
- (2012) M. Wenten et al. DIABETIC MEDICINE
- Protection of exenatide for retinal ganglion cells with different glucose concentrations
- (2012) Zheng Fu et al. PEPTIDES
- A cohort study of acute pancreatitis in relation to exenatide use
- (2011) D. D. Dore et al. DIABETES OBESITY & METABOLISM
- Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes
- (2011) J. Ma et al. DIABETIC MEDICINE
- National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants
- (2011) Mariel M Finucane et al. LANCET
- Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure
- (2010) Linda Rinaman BRAIN RESEARCH
- Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired -Cell Function?
- (2010) J. J. Meier et al. DIABETES
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men
- (2009) Richard D. Carr et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
- (2008) P. V. Højberg et al. DIABETOLOGIA
- Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome
- (2008) Karen Elkind-Hirsch et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More